CP-690,550 and Midazolam Drug-Drug Interaction Study

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

CP-690,550 and midazolam are metabolized by similar enzymes in the liver. This study is designed to assess whether co-administration of CP-690,500 and midazolam will effect the metabolism of midazolam in healthy volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer
• Treatments: Midazolam; Tofacitinib

Criteria

Inclusion Criteria:

• Healthy male and/or female (non-child bearing potential) subjects

Exclusion Criteria:

• Clinically significant infections within the past 3 months

• History of previously untreated infection with Mycobacterium tuberculosis

• Positive screening test for hepatitis B surface antigen, anti-hepatitis C antibody, or human immunodeficiency virus